董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Marvin Slosman | 男 | Director, President and Chief Executive Officer | 61 | 69.68万美元 | 未持股 | 2025-12-31 |
| Gary Roubin | 男 | Independent Director | 77 | 3.50万美元 | 未持股 | 2025-12-31 |
| Scott R. Ward | -- | Independent Director | -- | 未披露 | 未持股 | 2025-12-31 |
| Danny Lee Dearen | 男 | Director | -- | 未披露 | 未持股 | 2025-12-31 |
| Paul Stuka | 男 | Non-Executive Chairman of the Board | 70 | 6.20万美元 | 23.38 | 2025-12-31 |
| Raymond W. Cohen | 男 | Director | 66 | 未披露 | 未持股 | 2025-12-31 |
| Michael Berman | 男 | Independent Director | 67 | 4.10万美元 | 0.04 | 2025-12-31 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Marvin Slosman | 男 | Director, President and Chief Executive Officer | 61 | 69.68万美元 | 未持股 | 2025-12-31 |
| Andrea Tommasoli | 男 | Chief Operating Officer | 53 | 35.93万美元 | 未持股 | 2025-12-31 |
| Shane Gleason | 男 | Chief Commercial Officer | 51 | 未披露 | 未持股 | 2025-12-31 |
| Michael A. Lawless | -- | Chief Financial Officer | -- | 未披露 | 未持股 | 2025-12-31 |
| Pete Ligotti | -- | Executive Vice President and General Manager of U.S. | -- | 未披露 | 未持股 | 2025-12-31 |
| Patrick Verta | -- | Executive Vice President, Clinical and Medical Affairs | -- | 未披露 | 未持股 | 2025-12-31 |
董事简历
中英对照 | 中文 | 英文- Marvin Slosman
-
Marvin Slosman，自2020年1月1日起担任Inspiremd, Inc.总裁、首席执行官兼董事。Slosman先生从2019年5月至2019年12月担任MEDCURA Inc.的首席运营官。从2017年9月到2019年9月，Slosman先生担任Integra Life Sciences的商业顾问，监督国际商业战略和市场开发，Integra Life Sciences是骨科肢体手术、神经外科、重建和普通外科的领先创新者。从2010年到2014年，他担任Itamar Medical， Inc.（一家专注于心血管和睡眠诊断的医疗技术公司）的总裁。从2008年到2010年，他还担任Ovalum Vascular Ltd.的首席执行官。
Marvin Slosman,has served as Inspiremd, Inc. president, chief executive officer and director since January 1, 2020. Mr. Slosman has served as chief operating officer for MEDCURA Inc. from May 2019 to December 2019. From September 2017 to September 2019, Mr. Slosman served as a Business Consultant, overseeing international commercial strategy and market development, at Integra Life Sciences, a leading innovator in orthopedic extremity surgery, neurosurgery, and reconstructive and general surgery. From 2010 to 2014 Mr. Slosman served as President of Itamar Medical, Inc., a medical technology company focused on cardiovascular and sleep diagnostics. Mr. Slosman also served as chief executive officer of Ovalum Vascular Ltd. from 2008 to 2010. - Marvin Slosman，自2020年1月1日起担任Inspiremd, Inc.总裁、首席执行官兼董事。Slosman先生从2019年5月至2019年12月担任MEDCURA Inc.的首席运营官。从2017年9月到2019年9月，Slosman先生担任Integra Life Sciences的商业顾问，监督国际商业战略和市场开发，Integra Life Sciences是骨科肢体手术、神经外科、重建和普通外科的领先创新者。从2010年到2014年，他担任Itamar Medical， Inc.（一家专注于心血管和睡眠诊断的医疗技术公司）的总裁。从2008年到2010年，他还担任Ovalum Vascular Ltd.的首席执行官。
- Marvin Slosman,has served as Inspiremd, Inc. president, chief executive officer and director since January 1, 2020. Mr. Slosman has served as chief operating officer for MEDCURA Inc. from May 2019 to December 2019. From September 2017 to September 2019, Mr. Slosman served as a Business Consultant, overseeing international commercial strategy and market development, at Integra Life Sciences, a leading innovator in orthopedic extremity surgery, neurosurgery, and reconstructive and general surgery. From 2010 to 2014 Mr. Slosman served as President of Itamar Medical, Inc., a medical technology company focused on cardiovascular and sleep diagnostics. Mr. Slosman also served as chief executive officer of Ovalum Vascular Ltd. from 2008 to 2010.
- Gary Roubin
-
Gary Roubin自2020年10月13日起担任董事。Roubin博士于2010年共同创立了Essential Medical Inc.，该公司成功地将一种大口径血管闭合装置推向世界市场，最近被Teleflex Inc.收购。从2002年到2003年，Roubin博士在Angiomax产品发布期间担任The Medicines Company的首席医疗官。从2003年到2012年，Roubin博士担任纽约莱诺克斯山医院心脏和血管项目的部门主席兼首席服务官。从1989年到1997年，他担任阿拉巴马大学伯明翰分校（University of Alabama at Birmingham）的介入心脏病学主任，并于1989年加入该大学，担任医学和放射学教授，以及大学医院（University Hospital）的心导管实验室和介入心脏病学部门主任。2001年，Roubin博士在Mednova公司的成功中发挥了关键作用，Mednova公司被Abbott Vascular公司收购，从而在美国推出并营销了最畅销的颈动脉栓塞保护系统NAV6和支架系统（XACT）。1987年，他开发并放置了世界上第一个可膨胀的球囊冠状动脉支架。1984年，鲁宾博士加入埃默里大学的安德烈亚斯·格伦齐格继续他的博士后研究。他还因开发冠状动脉支架和首个FDA批准的冠状动脉支架而获得认可。Roubin博士在昆士兰大学医学院获得博士学位，在悉尼大学获得博士学位。Roubin博士是一位国际知名的介入心脏病专家，因其在颈动脉支架、栓塞和保护装置方面的开创性工作而获得认可，因此有资格在董事会任职。他还因开发冠状动脉支架和首个FDA批准的冠状动脉支架而获得认可。
Gary Roubin,has served as a director since October 13, 2020. Dr. Roubin cofounded Essential Medical Inc. in 2010, which has had success in bringing a large bore vascular closure device to world markets and was recently acquired by Teleflex Inc. From 2002 to 2003, Dr. Roubin served as Chief Medical Officer of the Medicines Company during the release of its Angiomax product. From 2003 to 2012, Dr. Roubin served as Department Chairman and Chief of Service of the Lenox Hill Hospital Cardiac and Vascular program in New York. From 1989 to 1997, he served as Chief of Interventional Cardiology at the University of Alabama at Birmingham, to which he joined in 1989 as Professor of Medicine and Radiology and Director of the Cardiac Catheterization Laboratories and Interventional Cardiology Section at the University Hospital. In 2001, Dr. Roubin played a pivotal role in the success of Mednova Inc., which was acquired by Abbott Vascular, resulting in the introduction and marketing in the U.S. of the top selling carotid embolic protection system (NAV6) and stent system (XACT). In 1987, he developed and placed the world's first balloon expandable coronary stent. In 1984, Dr. Roubin joined Andreas Gruentzig at Emory University to continue his post-doctoral research. He is also acknowledged for the development of coronary stenting and the first FDA-approved coronary stent. Dr. Roubin received his M.D. from the University of Queensland medical school and his Ph.D. from Sydney University. - Gary Roubin自2020年10月13日起担任董事。Roubin博士于2010年共同创立了Essential Medical Inc.，该公司成功地将一种大口径血管闭合装置推向世界市场，最近被Teleflex Inc.收购。从2002年到2003年，Roubin博士在Angiomax产品发布期间担任The Medicines Company的首席医疗官。从2003年到2012年，Roubin博士担任纽约莱诺克斯山医院心脏和血管项目的部门主席兼首席服务官。从1989年到1997年，他担任阿拉巴马大学伯明翰分校（University of Alabama at Birmingham）的介入心脏病学主任，并于1989年加入该大学，担任医学和放射学教授，以及大学医院（University Hospital）的心导管实验室和介入心脏病学部门主任。2001年，Roubin博士在Mednova公司的成功中发挥了关键作用，Mednova公司被Abbott Vascular公司收购，从而在美国推出并营销了最畅销的颈动脉栓塞保护系统NAV6和支架系统（XACT）。1987年，他开发并放置了世界上第一个可膨胀的球囊冠状动脉支架。1984年，鲁宾博士加入埃默里大学的安德烈亚斯·格伦齐格继续他的博士后研究。他还因开发冠状动脉支架和首个FDA批准的冠状动脉支架而获得认可。Roubin博士在昆士兰大学医学院获得博士学位，在悉尼大学获得博士学位。Roubin博士是一位国际知名的介入心脏病专家，因其在颈动脉支架、栓塞和保护装置方面的开创性工作而获得认可，因此有资格在董事会任职。他还因开发冠状动脉支架和首个FDA批准的冠状动脉支架而获得认可。
- Gary Roubin,has served as a director since October 13, 2020. Dr. Roubin cofounded Essential Medical Inc. in 2010, which has had success in bringing a large bore vascular closure device to world markets and was recently acquired by Teleflex Inc. From 2002 to 2003, Dr. Roubin served as Chief Medical Officer of the Medicines Company during the release of its Angiomax product. From 2003 to 2012, Dr. Roubin served as Department Chairman and Chief of Service of the Lenox Hill Hospital Cardiac and Vascular program in New York. From 1989 to 1997, he served as Chief of Interventional Cardiology at the University of Alabama at Birmingham, to which he joined in 1989 as Professor of Medicine and Radiology and Director of the Cardiac Catheterization Laboratories and Interventional Cardiology Section at the University Hospital. In 2001, Dr. Roubin played a pivotal role in the success of Mednova Inc., which was acquired by Abbott Vascular, resulting in the introduction and marketing in the U.S. of the top selling carotid embolic protection system (NAV6) and stent system (XACT). In 1987, he developed and placed the world's first balloon expandable coronary stent. In 1984, Dr. Roubin joined Andreas Gruentzig at Emory University to continue his post-doctoral research. He is also acknowledged for the development of coronary stenting and the first FDA-approved coronary stent. Dr. Roubin received his M.D. from the University of Queensland medical school and his Ph.D. from Sydney University.
- Scott R. Ward
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Danny Lee Dearen
-
Danny Lee Dearen，自2024年10月起担任Beta Bionics，Inc.（纳斯达克：BBNX）的董事会成员，该公司是一家医疗器械公司，从事创新解决方案的设计、开发和商业化，以改善需要胰岛素的糖尿病患者的健康和生活质量。Dearen先生此前曾任职于医疗器械公司Axonics, Inc.（纳斯达克：AXNX），于2013年10月至2018年8月担任首席运营官和首席财务官，并于2018年8月至2023年10月担任总裁和首席财务官。此前，他于2009年7月至2012年11月担任Vessix Vascular Inc.的首席运营官和首席财务官，于2004年12月至2008年11月担任Miraval Holding的首席财务官，并于1995年1月至2004年11月担任Q3DM、Fairbanks Systems Group、ESI Software、and Medication Delivery Devices的首席财务官TERM2。Dearen先生还担任多家私营公司的董事会成员，其中包括自2023年1月以来，经导管主动脉瓣置换系统的开发商和制造商JenaValve Technology，Inc.。他此前曾在Endotronix，Inc.的董事会任职，该公司是一家为心力衰竭患者提供数字健康管理解决方案的开发商和制造商，任职于2021年3月，直至2024年8月被爱德华兹生命科学收购。Dearen先生在南方卫理公会大学获得会计和商业学士学位，在波士顿学院获得工商管理硕士学位。
Danny Lee Dearen,has served as a member of the board of directors of Beta Bionics, Inc. (Nasdaq: BBNX), a medical device company engaged in the design, development, and commercialization of innovative solutions to improve the health and quality of life of insulin-requiring people with diabetes, since October 2024. Mr. Dearen previously worked at Axonics, Inc. (Nasdaq: AXNX), a medical device company, serving as Chief Operating Officer and Chief Financial Officer from October 2013 to August 2018 and as President and Chief Financial Officer from August 2018 to October 2023. Previously, he served as Chief Operating Officer and Chief Financial Officer of Vessix Vascular Inc. from July 2009 to November 2012, Chief Financial Officer of Miraval Holding from December 2004 to November 2008, and Chief Financial Officer of Q3DM, Fairbanks Systems Group, ESI Software, and Medication Delivery Devices from January 1995 to November 2004. Mr. Dearen also serves on the boards of several privately held companies, including JenaValve Technology, Inc., a developer and manufacturer of transcatheter aortic valve replacement systems, since January 2023. He previously served on the board of directors of Endotronix, Inc., a developer and manufacturer of digital health management solutions for patients suffering from heart failure, from March 2021 until its acquisition by Edwards Lifesciences in August 2024. Mr. Dearen received his B.B.A. in Accounting and Business from Southern Methodist University and his M.B.A. from Boston College. - Danny Lee Dearen，自2024年10月起担任Beta Bionics，Inc.（纳斯达克：BBNX）的董事会成员，该公司是一家医疗器械公司，从事创新解决方案的设计、开发和商业化，以改善需要胰岛素的糖尿病患者的健康和生活质量。Dearen先生此前曾任职于医疗器械公司Axonics, Inc.（纳斯达克：AXNX），于2013年10月至2018年8月担任首席运营官和首席财务官，并于2018年8月至2023年10月担任总裁和首席财务官。此前，他于2009年7月至2012年11月担任Vessix Vascular Inc.的首席运营官和首席财务官，于2004年12月至2008年11月担任Miraval Holding的首席财务官，并于1995年1月至2004年11月担任Q3DM、Fairbanks Systems Group、ESI Software、and Medication Delivery Devices的首席财务官TERM2。Dearen先生还担任多家私营公司的董事会成员，其中包括自2023年1月以来，经导管主动脉瓣置换系统的开发商和制造商JenaValve Technology，Inc.。他此前曾在Endotronix，Inc.的董事会任职，该公司是一家为心力衰竭患者提供数字健康管理解决方案的开发商和制造商，任职于2021年3月，直至2024年8月被爱德华兹生命科学收购。Dearen先生在南方卫理公会大学获得会计和商业学士学位，在波士顿学院获得工商管理硕士学位。
- Danny Lee Dearen,has served as a member of the board of directors of Beta Bionics, Inc. (Nasdaq: BBNX), a medical device company engaged in the design, development, and commercialization of innovative solutions to improve the health and quality of life of insulin-requiring people with diabetes, since October 2024. Mr. Dearen previously worked at Axonics, Inc. (Nasdaq: AXNX), a medical device company, serving as Chief Operating Officer and Chief Financial Officer from October 2013 to August 2018 and as President and Chief Financial Officer from August 2018 to October 2023. Previously, he served as Chief Operating Officer and Chief Financial Officer of Vessix Vascular Inc. from July 2009 to November 2012, Chief Financial Officer of Miraval Holding from December 2004 to November 2008, and Chief Financial Officer of Q3DM, Fairbanks Systems Group, ESI Software, and Medication Delivery Devices from January 1995 to November 2004. Mr. Dearen also serves on the boards of several privately held companies, including JenaValve Technology, Inc., a developer and manufacturer of transcatheter aortic valve replacement systems, since January 2023. He previously served on the board of directors of Endotronix, Inc., a developer and manufacturer of digital health management solutions for patients suffering from heart failure, from March 2021 until its acquisition by Edwards Lifesciences in August 2024. Mr. Dearen received his B.B.A. in Accounting and Business from Southern Methodist University and his M.B.A. from Boston College.
- Paul Stuka
-
Paul Stuka，自2011年8月8日起担任董事，自2017年6月2日起担任InspireMD, Inc.董事长。自2000年以来，他一直担任投资基金Osiris Partners， LLC的管理成员。在成立Osiris Partners， LLC之前，他在投资行业拥有35年的经验，是Longwood Partners的董事总经理，管理小型机构账户。1995年，他加入State Street Research and Management，担任Market Neutral和Mid Cap Growth Funds的经理。1986年至1994年，他担任Stuka Associates的普通合伙人，在那里他管理一家美国投资合伙企业。他的职业生涯始于1980年，担任Fidelity Management and Research的分析师。作为一名分析师，他跟踪了一系列广泛的行业，包括医疗保健、能源、交通、住宿和游戏。在他的职业生涯早期，他成为三个富达基金的助理投资组合经理，包括Select Healthcare Fund，Select Healthcare Fund被认为是截至1985年12月31日的五年期间美国表现最好的基金。从2013年到2022年，他担任Caliber Imaging & Diagnostics， Inc.（原Lucid， Inc.）的董事。
Paul Stuka,has served as a director since August 8, 2011 and has served as Inspiremd, Inc. chairman since June 2, 2017. Mr. Stuka has served as the managing member of Osiris Partners, LLC, an investment fund, since 2000. Prior to forming Osiris Partners, LLC, Mr. Stuka, with 35 years of experience in the investment industry, was a managing director of Longwood Partners, managing small cap institutional accounts. In 1995, Mr. Stuka joined State Street Research and Management as manager of its Market Neutral and Mid Cap Growth Funds. From 1986 to 1994, Mr. Stuka served as the general partner of Stuka Associates, where he managed a U.S.-based investment partnership. Mr. Stuka began his career in 1980 as an analyst at Fidelity Management and Research. As an analyst, Mr. Stuka followed a wide array of industries including healthcare, energy, transportation, and lodging and gaming. Early in his career he became the assistant portfolio manager for three Fidelity Funds, including the Select Healthcare Fund which was recognized as the top performing fund in the United States for the five-year period ending December 31, 1985. From 2013 to 2022 Mr. Stuka served as a director of Caliber Imaging & Diagnostics, Inc. (formerly Lucid, Inc.). - Paul Stuka，自2011年8月8日起担任董事，自2017年6月2日起担任InspireMD, Inc.董事长。自2000年以来，他一直担任投资基金Osiris Partners， LLC的管理成员。在成立Osiris Partners， LLC之前，他在投资行业拥有35年的经验，是Longwood Partners的董事总经理，管理小型机构账户。1995年，他加入State Street Research and Management，担任Market Neutral和Mid Cap Growth Funds的经理。1986年至1994年，他担任Stuka Associates的普通合伙人，在那里他管理一家美国投资合伙企业。他的职业生涯始于1980年，担任Fidelity Management and Research的分析师。作为一名分析师，他跟踪了一系列广泛的行业，包括医疗保健、能源、交通、住宿和游戏。在他的职业生涯早期，他成为三个富达基金的助理投资组合经理，包括Select Healthcare Fund，Select Healthcare Fund被认为是截至1985年12月31日的五年期间美国表现最好的基金。从2013年到2022年，他担任Caliber Imaging & Diagnostics， Inc.（原Lucid， Inc.）的董事。
- Paul Stuka,has served as a director since August 8, 2011 and has served as Inspiremd, Inc. chairman since June 2, 2017. Mr. Stuka has served as the managing member of Osiris Partners, LLC, an investment fund, since 2000. Prior to forming Osiris Partners, LLC, Mr. Stuka, with 35 years of experience in the investment industry, was a managing director of Longwood Partners, managing small cap institutional accounts. In 1995, Mr. Stuka joined State Street Research and Management as manager of its Market Neutral and Mid Cap Growth Funds. From 1986 to 1994, Mr. Stuka served as the general partner of Stuka Associates, where he managed a U.S.-based investment partnership. Mr. Stuka began his career in 1980 as an analyst at Fidelity Management and Research. As an analyst, Mr. Stuka followed a wide array of industries including healthcare, energy, transportation, and lodging and gaming. Early in his career he became the assistant portfolio manager for three Fidelity Funds, including the Select Healthcare Fund which was recognized as the top performing fund in the United States for the five-year period ending December 31, 1985. From 2013 to 2022 Mr. Stuka served as a director of Caliber Imaging & Diagnostics, Inc. (formerly Lucid, Inc.).
- Raymond W. Cohen
-
Raymond W. Cohen，他是子公司Kestra Medical Technologies， Inc.的董事会成员，自2024年以来一直担任该职务。Cohen先生自2025年起担任董事会成员。在加入公司之前，从2013年到2024年，Cohen先生担任Axonics， Inc.（纳斯达克股票代码：AXNX）的首席执行官和董事会成员，Axonics是一家医疗设备公司，拥有可植入技术，用于治疗膀胱和肠道疾病。Cohen先生目前担任Andera Partners的风险投资顾问，并担任SoniVie Ltd.的董事会主席。此前，他曾担任BioLife Solutions Inc.（纳斯达克代码：BLFS）和BiVACOR， Inc.的董事长，并担任Spectrum Pharmaceuticals Inc.（纳斯达克代码：SPPI）和Axonics， Inc.（纳斯达克代码：AXNX）的董事会成员。Cohen获得Binghamton大学的商业管理学士学位。
Raymond W. Cohen,Prior to joining Kestra as a director, from 2013 to late 2024, Mr. Cohen served as the Chief Executive Officer and a member of the board of directors of Axonics, Inc. (Nasdaq: AXNX), a medical device company with implantable technologies to treat bladder and bowel disorders, which was sold to Boston Scientific Corporation (NYSE: BSX) in November 2024. From 2023 to 2025, Mr. Cohen served as the chairman of the board of directors of SoniVie Ltd until it was acquired by Boston Scientific Corporation in March 2025. Mr. Cohen currently serves as chairman of the boards of directors of the privately held companies Nalu Medical Inc. and Archimedes Vascular, vice chairman of the board of directors of the privately held company Tulavi Medical, and a member of the board of directors of the private equity sponsor-backed company Spectrum Vascular. Previously, Mr. Cohen served as chairman of the board of directors of BioLife Solutions Inc. (Nasdaq: BLFS) and as a director of Spectrum Pharmaceuticals Inc. (Nasdaq: SPPI). Mr. Cohen received his B.S. in Business Management from Binghamton University. - Raymond W. Cohen，他是子公司Kestra Medical Technologies， Inc.的董事会成员，自2024年以来一直担任该职务。Cohen先生自2025年起担任董事会成员。在加入公司之前，从2013年到2024年，Cohen先生担任Axonics， Inc.（纳斯达克股票代码：AXNX）的首席执行官和董事会成员，Axonics是一家医疗设备公司，拥有可植入技术，用于治疗膀胱和肠道疾病。Cohen先生目前担任Andera Partners的风险投资顾问，并担任SoniVie Ltd.的董事会主席。此前，他曾担任BioLife Solutions Inc.（纳斯达克代码：BLFS）和BiVACOR， Inc.的董事长，并担任Spectrum Pharmaceuticals Inc.（纳斯达克代码：SPPI）和Axonics， Inc.（纳斯达克代码：AXNX）的董事会成员。Cohen获得Binghamton大学的商业管理学士学位。
- Raymond W. Cohen,Prior to joining Kestra as a director, from 2013 to late 2024, Mr. Cohen served as the Chief Executive Officer and a member of the board of directors of Axonics, Inc. (Nasdaq: AXNX), a medical device company with implantable technologies to treat bladder and bowel disorders, which was sold to Boston Scientific Corporation (NYSE: BSX) in November 2024. From 2023 to 2025, Mr. Cohen served as the chairman of the board of directors of SoniVie Ltd until it was acquired by Boston Scientific Corporation in March 2025. Mr. Cohen currently serves as chairman of the boards of directors of the privately held companies Nalu Medical Inc. and Archimedes Vascular, vice chairman of the board of directors of the privately held company Tulavi Medical, and a member of the board of directors of the private equity sponsor-backed company Spectrum Vascular. Previously, Mr. Cohen served as chairman of the board of directors of BioLife Solutions Inc. (Nasdaq: BLFS) and as a director of Spectrum Pharmaceuticals Inc. (Nasdaq: SPPI). Mr. Cohen received his B.S. in Business Management from Binghamton University.
- Michael Berman
-
Michael Berman，自2013年2月7日起担任InspireMD, Inc.董事。他是一名医疗设备企业家，自2014年以来一直在高潜力开发和早期商业公司工作。从2005年到2012年，Berman先生是BridgePoint Medical, Inc.的联合创始人兼董事长，该公司开发了治疗冠状动脉和周围血管慢性全闭塞的技术，该公司已出售给Boston Scientific。2007年至2011年，他也是Lutonix, Inc.的董事会成员，当时该公司被出售给C.R. Bard, Inc.。2011年至2018年，他担任Rebiotix Inc.（开发C Diff结肠炎创新治疗的公司）的联合创始人兼董事。Rebiotix于2018年被出售给Ferring Pharmaceuticals。从2014年到2018年，Berman先生担任Mazor Robotics（脊柱机器人手术的先驱公司）的董事。Mazor于2018年被出售给美敦力。他曾担任（i）自2011年起担任Cardiosonic, Inc.的顾问，并自2012年起担任Cardiosonic, Inc.的董事，Cardiosonic, Inc.是一家开发通过肾去神经控制降低高血压系统的公司；（ii）自2005年起担任PharmaCentra, LLC的董事，该公司创建可定制的营销计划，帮助制药公司与医生和患者沟通；（iii）自2018年起担任STMedical的董事。（iv）自2019年起担任CardiacSense Inc（一家开发智能手表生命体征监视器的医疗设备公司）的董事，（v）自2017年起担任Owlytics Healthcare的董事，（vi）自2013年起担任ClearCut Inc.（一家开发用于肿瘤边缘评估的MRI系统的医疗设备公司）的董事，（vii）自2013年起担任PulmOne Ltd.的董事。（viii）自2019年起担任医疗设备公司QArt的董事，（ix）自2014年起担任RiverVest Ventures的风险合伙人。（x）自2017年起担任Truleaf Medical的董事；（xi）自2022年起担任Kedma Solar Ltd的董事。
Michael Berman,has served as Inspiremd, Inc. director since February 7, 2013. Mr. Berman is a medical device entrepreneur who has worked with high-potential development and early-stage commercial companies since 2014. From 2005 to 2012, Mr. Berman was a co-founder and the chairman of BridgePoint Medical, Inc., which developed technology to treat coronary and peripheral vascular chronic total occlusions and which was sold to Boston Scientific. Mr. Berman was also a member of the board of Lutonix, Inc. from 2007 until 2011, when the company was sold to C.R. Bard, Inc. From 2011 to 2018, Mr. Berman served as a co-founder and director of Rebiotix Inc., a company developing an innovative treatment for C Diff colitis. Rebiotix was sold to Ferring Pharmaceuticals in 2018. From 2014 till 2018 Mr. Berman served as a director of Mazor Robotics, a company pioneering Spinal Robotic Surgery. Mazor was sold to Medtronic in 2018. Mr. Berman has served (i) since 2011 as an advisor to, and since 2012 as a director of, Cardiosonic, Inc., a company developing a system for hypertension reduction via renal denervation, (ii) since 2005 as a director of PharmaCentra, LLC, which creates customizable marketing programs that help pharmaceutical companies communicate with physicians and patients, (iii) since 2018 as a Director of STMedical, a medical device company that has developed a temporary stent for the treatment of chronic sinusitis, (iv) since 2019 as a director of CardiacSense Inc, a medical device company that has developed a smart watch vital sign monitor, (v) since 2017 as a Director of Owlytics Healthcare, (vi) since 2013 as a Director of ClearCut Inc., a medical device company that has developed an MRI system for tumor margin assessment, (vii) since 2013 as a director of PulmOne Ltd., a medical device company developing an innovative Pulmonary Function Testing system, (viii) since 2019 as a director of QArt, a medical device company, (ix) since 2014 as a venture partner at RiverVest Ventures. (x) since 2017 as a Director of Truleaf Medical and (xi) since 2022 as a Director of Kedma Solar Ltd. - Michael Berman，自2013年2月7日起担任InspireMD, Inc.董事。他是一名医疗设备企业家，自2014年以来一直在高潜力开发和早期商业公司工作。从2005年到2012年，Berman先生是BridgePoint Medical, Inc.的联合创始人兼董事长，该公司开发了治疗冠状动脉和周围血管慢性全闭塞的技术，该公司已出售给Boston Scientific。2007年至2011年，他也是Lutonix, Inc.的董事会成员，当时该公司被出售给C.R. Bard, Inc.。2011年至2018年，他担任Rebiotix Inc.（开发C Diff结肠炎创新治疗的公司）的联合创始人兼董事。Rebiotix于2018年被出售给Ferring Pharmaceuticals。从2014年到2018年，Berman先生担任Mazor Robotics（脊柱机器人手术的先驱公司）的董事。Mazor于2018年被出售给美敦力。他曾担任（i）自2011年起担任Cardiosonic, Inc.的顾问，并自2012年起担任Cardiosonic, Inc.的董事，Cardiosonic, Inc.是一家开发通过肾去神经控制降低高血压系统的公司；（ii）自2005年起担任PharmaCentra, LLC的董事，该公司创建可定制的营销计划，帮助制药公司与医生和患者沟通；（iii）自2018年起担任STMedical的董事。（iv）自2019年起担任CardiacSense Inc（一家开发智能手表生命体征监视器的医疗设备公司）的董事，（v）自2017年起担任Owlytics Healthcare的董事，（vi）自2013年起担任ClearCut Inc.（一家开发用于肿瘤边缘评估的MRI系统的医疗设备公司）的董事，（vii）自2013年起担任PulmOne Ltd.的董事。（viii）自2019年起担任医疗设备公司QArt的董事，（ix）自2014年起担任RiverVest Ventures的风险合伙人。（x）自2017年起担任Truleaf Medical的董事；（xi）自2022年起担任Kedma Solar Ltd的董事。
- Michael Berman,has served as Inspiremd, Inc. director since February 7, 2013. Mr. Berman is a medical device entrepreneur who has worked with high-potential development and early-stage commercial companies since 2014. From 2005 to 2012, Mr. Berman was a co-founder and the chairman of BridgePoint Medical, Inc., which developed technology to treat coronary and peripheral vascular chronic total occlusions and which was sold to Boston Scientific. Mr. Berman was also a member of the board of Lutonix, Inc. from 2007 until 2011, when the company was sold to C.R. Bard, Inc. From 2011 to 2018, Mr. Berman served as a co-founder and director of Rebiotix Inc., a company developing an innovative treatment for C Diff colitis. Rebiotix was sold to Ferring Pharmaceuticals in 2018. From 2014 till 2018 Mr. Berman served as a director of Mazor Robotics, a company pioneering Spinal Robotic Surgery. Mazor was sold to Medtronic in 2018. Mr. Berman has served (i) since 2011 as an advisor to, and since 2012 as a director of, Cardiosonic, Inc., a company developing a system for hypertension reduction via renal denervation, (ii) since 2005 as a director of PharmaCentra, LLC, which creates customizable marketing programs that help pharmaceutical companies communicate with physicians and patients, (iii) since 2018 as a Director of STMedical, a medical device company that has developed a temporary stent for the treatment of chronic sinusitis, (iv) since 2019 as a director of CardiacSense Inc, a medical device company that has developed a smart watch vital sign monitor, (v) since 2017 as a Director of Owlytics Healthcare, (vi) since 2013 as a Director of ClearCut Inc., a medical device company that has developed an MRI system for tumor margin assessment, (vii) since 2013 as a director of PulmOne Ltd., a medical device company developing an innovative Pulmonary Function Testing system, (viii) since 2019 as a director of QArt, a medical device company, (ix) since 2014 as a venture partner at RiverVest Ventures. (x) since 2017 as a Director of Truleaf Medical and (xi) since 2022 as a Director of Kedma Solar Ltd.
高管简历
中英对照 | 中文 | 英文- Marvin Slosman
Marvin Slosman，自2020年1月1日起担任Inspiremd, Inc.总裁、首席执行官兼董事。Slosman先生从2019年5月至2019年12月担任MEDCURA Inc.的首席运营官。从2017年9月到2019年9月，Slosman先生担任Integra Life Sciences的商业顾问，监督国际商业战略和市场开发，Integra Life Sciences是骨科肢体手术、神经外科、重建和普通外科的领先创新者。从2010年到2014年，他担任Itamar Medical， Inc.（一家专注于心血管和睡眠诊断的医疗技术公司）的总裁。从2008年到2010年，他还担任Ovalum Vascular Ltd.的首席执行官。
Marvin Slosman,has served as Inspiremd, Inc. president, chief executive officer and director since January 1, 2020. Mr. Slosman has served as chief operating officer for MEDCURA Inc. from May 2019 to December 2019. From September 2017 to September 2019, Mr. Slosman served as a Business Consultant, overseeing international commercial strategy and market development, at Integra Life Sciences, a leading innovator in orthopedic extremity surgery, neurosurgery, and reconstructive and general surgery. From 2010 to 2014 Mr. Slosman served as President of Itamar Medical, Inc., a medical technology company focused on cardiovascular and sleep diagnostics. Mr. Slosman also served as chief executive officer of Ovalum Vascular Ltd. from 2008 to 2010.- Marvin Slosman，自2020年1月1日起担任Inspiremd, Inc.总裁、首席执行官兼董事。Slosman先生从2019年5月至2019年12月担任MEDCURA Inc.的首席运营官。从2017年9月到2019年9月，Slosman先生担任Integra Life Sciences的商业顾问，监督国际商业战略和市场开发，Integra Life Sciences是骨科肢体手术、神经外科、重建和普通外科的领先创新者。从2010年到2014年，他担任Itamar Medical， Inc.（一家专注于心血管和睡眠诊断的医疗技术公司）的总裁。从2008年到2010年，他还担任Ovalum Vascular Ltd.的首席执行官。
- Marvin Slosman,has served as Inspiremd, Inc. president, chief executive officer and director since January 1, 2020. Mr. Slosman has served as chief operating officer for MEDCURA Inc. from May 2019 to December 2019. From September 2017 to September 2019, Mr. Slosman served as a Business Consultant, overseeing international commercial strategy and market development, at Integra Life Sciences, a leading innovator in orthopedic extremity surgery, neurosurgery, and reconstructive and general surgery. From 2010 to 2014 Mr. Slosman served as President of Itamar Medical, Inc., a medical technology company focused on cardiovascular and sleep diagnostics. Mr. Slosman also served as chief executive officer of Ovalum Vascular Ltd. from 2008 to 2010.
- Andrea Tommasoli
Andrea Tommasoli，自2023年3月19日起担任InspireMD, Inc.首席运营官。在托马索利先生被任命为首席运营官之前，他自2020年11月起担任InspireMD, Inc.全球销售和营销高级副总裁，为公司带来了超过20年的生命科学行业经验。在加入本公司之前，Tommasoli先生曾于2011年至2020年在医疗设备制造公司Integra LifeSciences担任商业领导职务，该公司生产用于皮肤再生、神经外科、重建和普通外科的产品，2017年1月至2020年10月担任间接市场高级总监，2014年6月至2016年12月担任欧洲专业外科解决方案销售总监，2011年7月至2014年6月担任欧洲、中东和非洲地区神经外科销售总监。在加入Integra之前，Tommasoli先生是Alticare的管理合伙人，Alticare是一家独立公司，2009年至2011年专注于医疗技术领域的初创公司和成长型公司，2007年至2009年担任法国圣犹达医疗神经调节部主任。Tommasoli先生在将创新医疗技术解决方案商业化方面拥有丰富的经验，这些解决方案可以改善和提高护理标准。托马索利在意大利博洛尼亚大学获得了核工程学士学位，在法国巴黎高等商学院获得了工商管理硕士学位。
Andrea Tommasoli,has served as Inspiremd, Inc. Chief Operating Officer since March 19, 2023. Prior to Mr. Tommasoli's appointment as Chief Operating Officer, he served as Inspiremd, Inc. Prior to joining the Company, Mr. Tommasoli held commercial leadership positions at Integra LifeSciences, a medical device manufacturing company that manufactures products for skin regeneration, neurosurgery, reconstructive and general surgery, from 2011 to 2020, serving as the Senior Director of Indirect Markets from January 2017 to October 2020, as Director of Sales for Specialty Surgical Solutions Europe from June 2014 to December 2016 and as Director of Sales for Neurosurgery EMEA from July 2011 to June 2014. Prior to joining Integra, Mr. Tommasoli was a Managing Partner at Alticare, an independent company focusing on start-ups and growth companies in the medtech business from 2009 to 2011 and was the Director of St. Jude Medical Neuromodulation division in France from 2007 to 2009. Mr. Tommasoli has vast experience in commercializing innovative medical technology solutions that improve and advance standard of care. Mr. Tommasoli received his B.A. in nuclear engineering from Bologna University, Italy and his M.B.A. from HEC Paris, France.- Andrea Tommasoli，自2023年3月19日起担任InspireMD, Inc.首席运营官。在托马索利先生被任命为首席运营官之前，他自2020年11月起担任InspireMD, Inc.全球销售和营销高级副总裁，为公司带来了超过20年的生命科学行业经验。在加入本公司之前，Tommasoli先生曾于2011年至2020年在医疗设备制造公司Integra LifeSciences担任商业领导职务，该公司生产用于皮肤再生、神经外科、重建和普通外科的产品，2017年1月至2020年10月担任间接市场高级总监，2014年6月至2016年12月担任欧洲专业外科解决方案销售总监，2011年7月至2014年6月担任欧洲、中东和非洲地区神经外科销售总监。在加入Integra之前，Tommasoli先生是Alticare的管理合伙人，Alticare是一家独立公司，2009年至2011年专注于医疗技术领域的初创公司和成长型公司，2007年至2009年担任法国圣犹达医疗神经调节部主任。Tommasoli先生在将创新医疗技术解决方案商业化方面拥有丰富的经验，这些解决方案可以改善和提高护理标准。托马索利在意大利博洛尼亚大学获得了核工程学士学位，在法国巴黎高等商学院获得了工商管理硕士学位。
- Andrea Tommasoli,has served as Inspiremd, Inc. Chief Operating Officer since March 19, 2023. Prior to Mr. Tommasoli's appointment as Chief Operating Officer, he served as Inspiremd, Inc. Prior to joining the Company, Mr. Tommasoli held commercial leadership positions at Integra LifeSciences, a medical device manufacturing company that manufactures products for skin regeneration, neurosurgery, reconstructive and general surgery, from 2011 to 2020, serving as the Senior Director of Indirect Markets from January 2017 to October 2020, as Director of Sales for Specialty Surgical Solutions Europe from June 2014 to December 2016 and as Director of Sales for Neurosurgery EMEA from July 2011 to June 2014. Prior to joining Integra, Mr. Tommasoli was a Managing Partner at Alticare, an independent company focusing on start-ups and growth companies in the medtech business from 2009 to 2011 and was the Director of St. Jude Medical Neuromodulation division in France from 2007 to 2009. Mr. Tommasoli has vast experience in commercializing innovative medical technology solutions that improve and advance standard of care. Mr. Tommasoli received his B.A. in nuclear engineering from Bologna University, Italy and his M.B.A. from HEC Paris, France.
- Shane Gleason
Shane Gleason，自2023年3月1日起担任Inspiremd，Inc.北美总经理和全球营销副总裁。在加入InspireMD, Inc.之前，格里森先生从2021年起担任苏尔医疗诊断血管介入销售副总裁。在此之前，他曾于2019年至2021年在人工心脏瓣膜和血流动力学监测技术开发商Edwards Life Sciences（纽约证券交易所代码：EW）担任美国市场营销高级总监，在此之前，他于2017年至2019年担任Nuvaira，Inc.的首席商务官，Nuvaira，Inc.是一家私有的COPD疗法开发商，旨在保护患者的肺部健康。在他职业生涯的早期，格里森曾于2015年至2016年在卡地纳健康公司Cordis（纽约证券交易所代码：CAH）、2012年至2015年在Trivascular科技（恩多勒吉克斯的一部分）和2007年至2010年在Abbott Vascular（纽约证券交易所代码：ABT）担任销售和营销领导职务，在那里他推出了第二个获得FDA批准的颈动脉支架系统。Gleason先生在弗吉尼亚理工学院和州立大学获得科学、工程科学和力学学士学位，在马里兰大学史密斯商学院获得工商管理硕士学位。
Shane Gleason,has served as Inspiremd, Inc. general manager of North America and vice president of global marketing since March 1, 2023. Prior to joining Inspiremd, Inc. , Mr. Gleason served as served as vice president of sales, vascular interventions at Surmodics from 2021. Before that, from 2019 to 2021, he served as senior director, US marketing at Edwards Life Sciences (NYSE: EW), a developer of artificial heart valve and hemodynamic monitoring technologies, and, before that, from 2017 to 2019 as, chief commercial officer at Nuvaira, Inc., a privately held developer of COPD therapies that preserve patient lung health. Earlier in his career, Mr. Gleason held sales and marketing leadership roles at Cordis, a Cardinal Health company (NYSE: CAH) from 2015 to 2016, Trivascular Technologies (part of Endologix) from 2012 to 2015, and Abbott Vascular (NYSE: ABT) from 2007 to 2010, where he launched the second FDA approved carotid stent system. Mr. Gleason received a Bachelor of Science, Engineering Science and Mechanics from Virginia Polytechnic Institute and State University and a Master of Business Administration from the University of Maryland Smith School of Business.- Shane Gleason，自2023年3月1日起担任Inspiremd，Inc.北美总经理和全球营销副总裁。在加入InspireMD, Inc.之前，格里森先生从2021年起担任苏尔医疗诊断血管介入销售副总裁。在此之前，他曾于2019年至2021年在人工心脏瓣膜和血流动力学监测技术开发商Edwards Life Sciences（纽约证券交易所代码：EW）担任美国市场营销高级总监，在此之前，他于2017年至2019年担任Nuvaira，Inc.的首席商务官，Nuvaira，Inc.是一家私有的COPD疗法开发商，旨在保护患者的肺部健康。在他职业生涯的早期，格里森曾于2015年至2016年在卡地纳健康公司Cordis（纽约证券交易所代码：CAH）、2012年至2015年在Trivascular科技（恩多勒吉克斯的一部分）和2007年至2010年在Abbott Vascular（纽约证券交易所代码：ABT）担任销售和营销领导职务，在那里他推出了第二个获得FDA批准的颈动脉支架系统。Gleason先生在弗吉尼亚理工学院和州立大学获得科学、工程科学和力学学士学位，在马里兰大学史密斯商学院获得工商管理硕士学位。
- Shane Gleason,has served as Inspiremd, Inc. general manager of North America and vice president of global marketing since March 1, 2023. Prior to joining Inspiremd, Inc. , Mr. Gleason served as served as vice president of sales, vascular interventions at Surmodics from 2021. Before that, from 2019 to 2021, he served as senior director, US marketing at Edwards Life Sciences (NYSE: EW), a developer of artificial heart valve and hemodynamic monitoring technologies, and, before that, from 2017 to 2019 as, chief commercial officer at Nuvaira, Inc., a privately held developer of COPD therapies that preserve patient lung health. Earlier in his career, Mr. Gleason held sales and marketing leadership roles at Cordis, a Cardinal Health company (NYSE: CAH) from 2015 to 2016, Trivascular Technologies (part of Endologix) from 2012 to 2015, and Abbott Vascular (NYSE: ABT) from 2007 to 2010, where he launched the second FDA approved carotid stent system. Mr. Gleason received a Bachelor of Science, Engineering Science and Mechanics from Virginia Polytechnic Institute and State University and a Master of Business Administration from the University of Maryland Smith School of Business.
- Michael A. Lawless
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Pete Ligotti
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Patrick Verta
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介